Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system

Pediatric Blood and Cancer

Volumn 54, Issue 4, 2010, Pages 591-595

  Gilheeney, Stephen W ^a   Khakoo, Yasmin ^a   Souweidane, Mark ^a   Wolden, Suzanne ^a   Boulad, Farid ^a   Dunkel, Ira J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Pediatrics; Recurrent glioma; Recurrent medulloblastoma

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; TOPOTECAN;

ADOLESCENT; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOMA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG ERUPTION; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MEDULLOBLASTOMA; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PINEOBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETINOBLASTOMA; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; THIOTEPA; TOPOTECAN; YOUNG ADULT;

EID: 77649150719     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22347     Document Type: Article

References (14)

1. Packer R, Zhou T, Holmes E, et al. Timing, Pattern of Relapse, and Post-relapse Survival in Children with Medullloblastoma: Results from Four Consecutibve Children's Oncology Group (COG) Studies Performed Over the Past 20 Years, 2008; Chicago, IL.
2. Finlay J, Dhall G, Boyett J, et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: Outcome compared with conventional chemotherapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:806-811.
3. Freeman B, Iacono L, Panetta J, et al. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. Neuro-Oncology 2006;8: 89-95.
4. Motl S, Zhuang Y,Waters C, et al. Pharmacokinetic considerations in the treatment of CNS Tumors. Clin Pharmacokinet 2006;45: 871-903.
5. Feun L, Savaraj N. Topoisomerase I inhibitors for the treatment of brain tumors. Expert Rev Anticancer Ther 2008;8:707-716.
6. Wolff J, Finlay J. High-dose chemotherapy in childhood brain tumors. Onkologie 2004;27:239-245.
7. Cheuk D, Lee T, Chiang A, et al. Autologous hematopoietic stem cell transplantation for high-risk brain tumors in children. J Neurooncol 2008;86:337-347.
8. Gururangan S, Dunkel I, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16:2486-2493.
9. Gururangan S, Krauser J, Watral M, et al. Efficacy of high-dose chemotehrapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology 2008;10:745-751.
10. Papdakis V, Dunkel I, Cramer L, et al. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrowrescue for the treatment of high risk central nervous system tumors. Bone Marrow Transplant 2000;26:153-160.
11. Kushner B, Cheung N-K, Kramer K, et al. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 2001;28:551-556.
12. Park J, Slattery J, Gooley T, et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Peditaric Oncol 2000;35:719-723.
13. Perez-Martinez A, Lassaletta A, Gonzalez-Vincent M, et al. High dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neuro-Oncol 2005;71:33-38.
14. Shih C-S, Hale G, Gronewold L, et al. High-dose chemotehrapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 2008;112:1345-1353.